Theendothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo

Blood

Volumn 124, Issue 7, 2014, Pages 1157-1165

  Pavani, Giulia ^a   Ivanciu, Lacramioara ^a   Faella, Armida ^a   Marcos Contreras, Oscar A ^a   Margaritis, Paris ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ENDOTHELIAL PROTEIN C RECEPTOR; IMMUNOGLOBULIN G1; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN; ACTIVATED PROTEIN C RECEPTOR; AMINO ACID; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; CELL SURFACE RECEPTOR; PROTEIN BINDING; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; BLOOD VESSEL INJURY; CHIMERA; CONTROLLED STUDY; ENTHALPY; ENTROPY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; HUMAN CELL; ISOTHERMAL TITRATION CALORIMETRY; MACROVASCULAR INJURY; MALE; MICROCIRCULATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STOICHIOMETRY; THROMBOELASTOGRAPH; ANIMAL; BINDING COMPETITION; BINDING SITE; BLOOD; C57BL MOUSE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HAMSTER; KINETICS; METABOLISM; THROMBOELASTOGRAPHY;

1-CARBOXYGLUTAMIC ACID; AMINO ACIDS; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CHO CELLS; CRICETINAE; CRICETULUS; FACTOR VIIA; HEMOPHILIA A; HEMOSTASIS; HUMANS; KINETICS; MALE; MICE, INBRED C57BL; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBOPLASTIN;

EID: 84905993504     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-567297     Document Type: Article

References (49)

1. Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders - a 2006 review. Haemophilia. 2006;12(5):457-472. (Pubitemid 44227588)
2. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154(8):516-522.
3. Witmer CM, Huang YS, Lynch K, Raffini LJ, Shah SS. Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr. 2011;158(5):820-825.
4. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791-1800.
5. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154(8):529-540.
6. Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler Thromb Vasc Biol. 2003;23(1):123-129. (Pubitemid 36091636)
7. van 't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95(4):1330-1335. (Pubitemid 30099843)
8. Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost. 2007;5(4):774-780. (Pubitemid 46563577)
9. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38(4 Suppl 12):6-9. (Pubitemid 33123950)
10. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99(3):542-547. (Pubitemid 27519853)
11. de Paula EV, Kavakli K, Mahlangu J, et al; 1804 (adept(TM)1) Investigators. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012;10(1):81-89.
12. Hoffman M, Volovyk Z, Persson E, Gabriel DA, Ezban M, Monroe DM. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost. 2011;9(4):759-766.
13. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA. 2001;98(24):13583-13588. (Pubitemid 33115941)
14. Feng D, Whinna H, Monroe D, Stafford DW. FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood. 2014;123(11):1764-1766.
15. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32(Suppl 1):49-60.
16. Preston RJ, Ajzner E, Razzari C, et al. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem. 2006;281(39):28850- 28857. (Pubitemid 44507028)
17. Ghosh S, Pendurthi UR, Steinoe A, Esmon CT, Rao LV. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem. 2007;282(16):11849-11857. (Pubitemid 47100682)
18. Clark CA, Vatsyayan R, Hedner U, Esmon CT, Pendurthi UR, Rao LV. Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa. J Thromb Haemost. 2012;10(11):2383-2391.
19. Disse J, Petersen HH, Larsen KS, et al. The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem. 2011;286(7):5756-5767.
20. López-Sagaseta J, Montes R, Puy C, Díez N, Fukudome K, Hermida J. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J Thromb Haemost. 2007;5(9):1817-1824. (Pubitemid 47288936)
21. Puy C, Hermida J, Montes R. Factor X and factor VII binding to endothelial protein C receptor differs between species. J Thromb Haemost. 2011;9(6):1255-1257.
22. Margaritis P, Roy E, Faella A, et al. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo. Blood. 2011;117(15):3974-3982.
23. Petersen LC, Nørby PL, Branner S, et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res. 2005;116(1):75-85. (Pubitemid 40546328)
24. Sen P, Clark CA, Gopalakrishnan R, et al. Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems. Thromb Haemost. 2012;107(5):951-961.
25. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest. 2004;113(7):1025-1031. (Pubitemid 38544124)
26. Larson PJ, Camire RM, Wong D, et al. Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry. 1998;37(14):5029-5038. (Pubitemid 28175985)
27. Camire RM, Larson PJ, Stafford DW, High KA. Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry. 2000;39(46):14322-14329.
28. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675.
29. Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood. 2011;117(1):290-298.
30. Ivanciu L, Toso R, Margaritis P, et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol. 2011;29(11):1028-1033.
31. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90(10):3962-3966. (Pubitemid 27484049)
32. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
33. Regan LM, Mollica JS, Rezaie AR, Esmon CT. The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C. J Biol Chem. 1997;272(42):26279-26284. (Pubitemid 27458839)
34. Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X, Rezaie AR, Esmon CT. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem. 1996;271(29):17491-17498. (Pubitemid 26244316)
35. Leavitt S, Freire E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol. 2001;11(5):560-566. (Pubitemid 32972017)
36. Banner DW, D'Arcy A, Chène C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996;380(6569):41-46. (Pubitemid 26076234)
37. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost. 2008;100(4):557-562.
38. Deane R, LaRue B, Sagare AP, Castellino FJ, Zhong Z, Zlokovic BV. Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cereb Blood Flow Metab. 2009;29(1):25-33.
39. Laszik Z, Mitro A, Taylor FB Jr, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 1997;96(10):3633-3640. (Pubitemid 27513443)
40. Atkinson BT, Jasuja R, Chen VM, Nandivada P, Furie B, Furie BC. Laser-induced endothelial cell activation supports fibrin formation. Blood. 2010;116(22):4675-4683.
41. Kroh HK, Panizzi P, Tchaikovski S, et al. Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo. J Biol Chem. 2011;286(26):23345-23356.
42. Li W, Zheng X, Gu J, et al. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost. 2005;3(7):1351-1359. (Pubitemid 41725187)
43. Zheng X, Li W, Song Y, et al. Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost. 2007;5(7):1394-1400. (Pubitemid 46965366)
44. Sen P, Gopalakrishnan R, Kothari H, et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood. 2011;117(11):3199-3208.
45. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost. 2013;11(Suppl 1):84-98.
46. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904-1913. (Pubitemid 47288949)
47. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007;5(7):1403-1408. (Pubitemid 46965368)
48. Aljamali MN, Margaritis P, Schlachterman A, et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest. 2008;118(5):1825-1834. (Pubitemid 351632385)
49. Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood. 2009;113(16):3682- 3689.